Literature DB >> 1725731

Humoral immune responses to tumor-associated carbohydrate antigens.

K O Lloyd1.   

Abstract

Antibodies to carbohydrate structures are quite commonly found in human sera. Normal individuals, as well as individuals with autoimmune diseases and cancer, produce antibodies reacting with a variety of carbohydrate determinants. These determinants can be expressed on glycoproteins, mucins or glycosphingolipids. For understanding a possible immune response to cancer, the challenge is to determine which, if any, of the serum antibodies are related to the tumor state. This problem has been approached by analyzing the specificity of serum antibodies and, more recently, by producing monoclonal antibodies from the lymphocytes of cancer patients. Malignant melanoma and lung cancer have been the main focus of the monoclonal antibody approach. Melanoma patients' lymphocytes have, in general, yielded anti-ganglioside antibodies whereas anti-neutral glycolipid antibodies were isolated from lung cancer patients. Although these studies provide reagents for potential use in the in vivo diagnosis and therapy of cancer, the significance of these antibodies for an immune response to cancer needs to be further explored.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725731

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  14 in total

1.  Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.

Authors:  Jiatong Guo; Wenjie Jiang; Qingjiang Li; Mohit Jaiswal; Zhongwu Guo
Journal:  Carbohydr Res       Date:  2020-03-31       Impact factor: 2.104

2.  Synthesis of the Cancer-Associated KH-1 Antigen by Block Assembly of Its Backbone Structure Followed by One-Step Grafting of Three Fucose Residues.

Authors:  Qingjiang Li; Zhongwu Guo
Journal:  Org Lett       Date:  2017-11-29       Impact factor: 6.005

3.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.

Authors:  S Mao; C Gao; C H Lo; P Wirsching; C H Wong; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 4.  Signaling domains of cancer-associated glycolipids.

Authors:  Koichi Furukawa; Yuhsuke Ohmi; Kazunori Hamamura; Yuji Kondo; Yuki Ohkawa; Kei Kaneko; Noboru Hashimoto; Farhana Yesmin; Robiul H Bhuiyan; Orie Tajima; Keiko Furukawa
Journal:  Glycoconj J       Date:  2022-03-22       Impact factor: 2.916

Review 5.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

6.  A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.

Authors:  Rebecca M Wilson; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2013-09-18       Impact factor: 15.419

7.  Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.

Authors:  Ramila Philip; Sidhartha Murthy; Jonathan Krakover; Gomathinayagam Sinnathamby; Jennifer Zerfass; Lorraine Keller; Mohan Philip
Journal:  J Proteome Res       Date:  2007-06-05       Impact factor: 4.466

8.  Cancer antigens: immune recognition of self and altered self.

Authors:  A N Houghton
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

9.  Synthesis and characterization of a novel chemically designed (Globo)3-DTPA-KLH antigen.

Authors:  Mehdi Hajmohammadi; Seyed Davar Siadat; Masoud Ghorbani; Mehdi Shafiee Ardestani; Shahram Teimourian; Vahid Asgari; Reza Ahangari Cohan; Mostafa Hajmohammadi; Akram Hajmohammadi; Ramezan Behzadi; Saied Rajab Nezhad; Nabiollah Namvar Asl
Journal:  Drug Des Devel Ther       Date:  2014-12-22       Impact factor: 4.162

10.  Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.

Authors:  I Hara; Y Takechi; A N Houghton
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.